Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Silpe

Vascular Surgery New Hyde Park, NY Medical Doctor

NPI 1770903825 CMS profile 11300292

1999 Marcus Ave Ste 106B, New Hyde Park, NY 11042

Open in the dashboard

General payments

$131,777

180 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$43,964 paid to institutions, not to them · program year 2025

Through program year 2025, Jeffrey Silpe of New Hyde Park, NY is reported in the CMS Open Payments database as having received $131,777 across 180 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $43,964 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84,153 93
2024 General $39,115 48
2023 General $7,289 24
2022 General $684 8
2021 General $536 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Silpe
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Jeffrey Silpe were reported at $84,153. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Jeffrey Silpe Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $0 $348 $118–$1,110 $114
2021 $536 $471 $158–$1,421 $132
2022 $684 $725 $222–$2,183 $149
2023 $7,289 $836 $257–$2,440 $160
2024 $39,115 $909 $252–$2,619 $164
2025 $84,153 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Stryker Corporation $77,454 53 payments
  2. Bard Peripheral Vascular, Inc. $23,050 34 payments
  3. Inari Medical, Inc. $8,576 16 payments
  4. Medtronic, Inc. $8,425 40 payments
  5. Medical Device Business Services, Inc. $5,499 10 payments
  6. Ethicon US, LLC $4,452 2 payments
  7. Endologix, Inc. $2,807 11 payments
  8. Penumbra, Inc. $417 6 payments
  9. Shockwave Medical, Inc $342 2 payments
  10. CVRx, Inc. $293 2 payments
  11. Other $461 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $88,239 29 payments
  2. Travel and Lodging $26,691 45 payments
  3. Food and Beverage $11,348 102 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,500 4 payments
Products named General payments · program years 2021–2025
  1. FLOWTRIEVER CATHETER, S $70,647 45 payments
  2. CT THROMBECTOMY SYSTEM KIT $70,333 43 payments
  3. LIMFLOW SYSTEM Inari Medical $6,505 14 payments
  4. LIMFLOW SYSTEM Clti $6,433 7 payments
  5. HawkOne $6,377 4 payments
  6. PROLENE $4,841 3 payments
  7. SURGICEL NU-KNIT $4,841 3 payments
  8. STRATAFIX $4,452 2 payments
  9. VISTASEAL $4,452 2 payments
  10. DERMABOND PRINEO $4,452 2 payments
  11. Other $18,818 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

84

Median for Vascular Surgery: 122

Drug cost

$443

Median for Vascular Surgery: $14,135

Branded share of claims

0%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cilostazol Generic 15 $369
Alprazolam Generic 69 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$215,058

Medicare's payments for the services billed

Medicare patients

316

Average age 76

Services billed

1,141

153 women, 163 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Ischemic heart disease 60%
Arthritis 60%
Chronic kidney disease 44%
Heart failure 43%
Atrial fibrillation 37%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record